SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials

BACKGROUND: Type 2 diabetes is closely related to an increased risk of atrial fibrillation (AF) and atrial flutter (AFL). Whether sodium-glucose cotransporter 2 (SGLT2) inhibitors can attenuate AF/AFL progression remains unclear. METHODS: We searched electronic databases (PubMed, Embase and Clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wen-jie, Chen, Xing-qing, Xu, Ling-ling, Li, Yuan-qing, Luo, Bi-hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448518/
https://www.ncbi.nlm.nih.gov/pubmed/32847602
http://dx.doi.org/10.1186/s12933-020-01105-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448518/
https://www.ncbi.nlm.nih.gov/pubmed/32847602
http://dx.doi.org/10.1186/s12933-020-01105-5

Ejemplares similares